Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study
Max E. Butterfield(Point Loma Nazarene University), Joel Young(Wayne State University), Jaime Saal(Rochester Center for Behavioral Medicine), Benjamin Young(Cornell University)
Cited by 28
Related Papers
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions
|Nature Communications|2021|189
Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions
|bioRxiv (Cold Spring Harbor Laboratory)|2020|96
Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
|CNS Spectrums|2009|93
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder
|Journal of the American Academy of Child & Adolescent Psychiatry|2015|63
Once-Daily Treatment With Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder
|Clinical Neuropharmacology|2011|61